指南与共识医院感染防控新发突发、热带与寄生虫病

ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向与生物治疗安全性的共识文件:感染病学视角(免疫检查点抑制剂、细胞黏附抑制剂、1-磷酸鞘氨醇受体调节剂和蛋白酶体抑制剂)

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
指南 / 共识 · Clin Microbiol Infect · 2018-02-07

本文件为 ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向与生物治疗安全性的共识文件之一,从感染病学视角综述免疫检查点抑制剂、LFA-3 靶向药、细胞黏附抑制剂、1-磷酸鞘氨醇受体调节剂和蛋白酶体抑制剂的感染安全性并给出预防建议。文献来源为 Medline 计算机检索,检索词按各药物或治疗类别设定。

要点

  • CTLA-4 及 PD-1/PD-L1 靶向药本身似不增加感染风险,但可致需额外免疫抑制的免疫相关不良反应。
  • 那他珠单抗和依法利珠单抗治疗中可能出现进行性多灶性白质脑病(PML),维多珠单抗迄今未见报告。
  • 芬戈莫德及蛋白酶体抑制剂增加水痘-带状疱疹病毒感染风险,可考虑或推荐(伐)阿昔洛韦预防。

核心结论

  • CTLA-4 与 PD-1/PD-L1 靶向药本身似不增加感染风险,但可诱发需额外免疫抑制的免疫相关不良反应。
  • 阿法西普虽与 CD4+ T 细胞淋巴细胞减少相关,但未观察到机会性感染。
  • 那他珠单抗和依法利珠单抗治疗期间可能发生进行性多灶性白质脑病(PML),维多珠单抗迄今未见报告。
  • 对于 PML 高风险患者(抗 JC 多瘤病毒血清学阳性且血清抗体指数>1.5、治疗时间≥48 个月),应仔细权衡继续那他珠单抗治疗的获益-风险比。

研究设计与样本

  • ESCMID 免疫功能受损宿主感染研究组(ESGICH)共识文件,以计算机检索 Medline、按各药物或治疗类别设定 MeSH 主题词进行综述。

主要发现

  • CTLA-4 与 PD-1/PD-L1 靶向药本身似不增加感染风险,但可诱发需额外免疫抑制的免疫相关不良反应。
  • 阿法西普与 CD4+ T 细胞淋巴细胞减少相关,但未观察到机会性感染。
  • 那他珠单抗(抗 α4-整合素单克隆抗体)和依法利珠单抗(抗 CD11a 单克隆抗体)治疗期间可能发生 PML,维多珠单抗(抗 α4β7 单克隆抗体)迄今未见报告。
  • 芬戈莫德引起显著的外周血淋巴细胞减少,并增加水痘-带状疱疹病毒(VZV)感染风险。
  • 蛋白酶体抑制剂同样增加 VZV 感染风险。

关键数值与推荐

  • 对 PML 高风险患者(抗 JC 多瘤病毒血清学阳性且血清抗体指数>1.5、治疗时间≥48 个月),应仔细权衡继续那他珠单抗治疗的获益-风险比。
  • 芬戈莫德治疗期间可考虑用(伐)阿昔洛韦预防并考虑 VZV 疫苗接种。
  • 蛋白酶体抑制剂治疗时推荐用(伐)阿昔洛韦进行抗病毒预防。
  • 多发性骨髓瘤患者若存在额外危险因素(即大剂量糖皮质激素),可考虑抗肺孢子菌预防。

临床怎么用

  • 临床医生应认识到接受免疫检查点抑制剂者可能发生免疫相关不良反应,接受细胞黏附抑制剂者可能发生 PML。
  • 对 PML 高风险的那他珠单抗治疗患者,应仔细权衡继续治疗的获益-风险比。
  • 芬戈莫德治疗时可考虑(伐)阿昔洛韦预防并考虑 VZV 疫苗接种;蛋白酶体抑制剂治疗时推荐(伐)阿昔洛韦抗病毒预防。
  • 多发性骨髓瘤患者合并额外危险因素(即大剂量糖皮质激素)时,可考虑抗肺孢子菌预防。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies. AIMS: To review, from an infectious diseases perspective, the safety profile of immune checkpoint inhibitors, LFA-3-targeted agents, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors, and to suggest preventive recommendations. SOURCES: Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death (PD)-1/PD-1 ligand 1 (PD-L1)-targeted agents do not appear to intrinsically increase the risk of infection but can induce immune-related adverse effects requiring additional immunosuppression. Although CD4+ T-cell lymphopenia is associated with alefacept, no opportunistic infections have been observed. Progressive multifocal leukoencephalopathy (PML) may occur during therapy with natalizumab (anti-α4-integrin monoclonal antibody (mAb)) and efalizumab (anti-CD11a mAb), but no cases have been reported to date with vedolizumab (anti-α4β7 mAb). In patients at high risk for PML (positive anti-JC polyomavirus serology with serum antibody index >1.5 and duration of therapy ≥48 months), the benefit-risk ratio of continuing natalizumab should be carefully considered. Fingolimod induces profound peripheral blood lymphopenia and increases the risk of varicella zoster virus (VZV) infection. Prophylaxis with (val)acyclovir and VZV vaccination should be considered. Proteasome inhibitors also increase the risk of VZV infection, and antiviral prophylaxis with (val)acyclovir is recommended. Anti-Pneumocystis prophylaxis may be considered in myeloma multiple patients with additional risk factors (i.e. high-dose corticosteroids). IMPLICATIONS: Clinicians should be aware of the risk of immune-related adverse effects and PML in patients receiving immune checkpoint and cell adhesion inhibitors respectively.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Redelman-Sidi G, Michielin O, Cervera C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect. 2018. PMID: 29427804. doi:10.1016/j.cmi.2018.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。